Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α
- PMID: 40993371
- DOI: 10.1038/s44161-025-00712-3
Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α
Abstract
Endurance exercise promotes adaptive growth and improved function of myocytes, which is supported by increased mitochondrial activity. In skeletal muscle, these benefits are in part transcriptionally coordinated by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). The importance of PGC-1α to exercise-induced adaptations in the heart has been unclear. Here we show that deleting PGC-1α specifically in cardiomyocytes prevents the expected benefits from exercise training and instead leads to heart failure after just 6 weeks of training. Consistent with this, in humans, rare genetic variants in PPARGC1A, which encodes PGC-1α, are associated with increased risk of heart failure. In this model, we identify growth differentiation factor 15 (GDF15) as a key heart-secreted mediator that contributes to this dysfunction. Blocking cardiac Gdf15 expression improves cardiac performance and exercise capacity in these mice. Finally, in human heart tissue, lower cardiomyocyte PPARGC1A expression is associated with higher GDF15 expression and reduced cardiomyocyte density. These findings uncover a crucial role for cardiomyocyte PGC-1α in enabling healthy cardiac adaptation to exercise in part through suppression of GDF15.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: B.M.S. is an inventor on patent WO2015051007A1; the patent applicant is Dana Farber Cancer Institute. Inventors include B.M.S. and Christiane D. Wrann (not affiliated with this study). The application number is WO2015051007A1. Patent is currently active. No aspect of the current paper is covered in the patent application. A.A. is an inventor on patent US20210163495A1; the patent applicant is The General Hospital Corporation. Inventors include A.A. and several investigators unaffiliated with this study (R. T. Peterson, Y. Liu, B. Zheng, Y. Wang). The application number is US20210163495A1. The patent is currently active. No aspect of this paper is covered in the patent application. J.D.R. and A.R. are inventors on patent US11834508B2; patent applicants are Norvartis AG and Beth Israel Deaconess Medical Center. Inventors include J.D.R., A.R. and D. J. Glass (not affiliated with this study). The application number is US11834508B2. The patent is currently active. No aspect of the current study is covered in the patent application. In addition, we note the additional following competing interests. B.M.S. is an academic cofounder and consultant for Aevum Therapeutics, all unrelated to this current work. J.R. is a consultant for Takeda Neurosciences, unrelated to the current work. S.P. is currently employed by the Novartis Institute of Biomedical Research. J.D.R. has received research support from Amgen, Genentech and Keros, all unrelated to this current work. A.R. is a scientific founder of Thryv Therapeutics, unrelated to this current work. M.N. has received funds or material research support from Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon, Verseau Therapeutics and Bitterroot, all unrelated to the current work. A.A. reports on the Board of Directors of Corventum. The other authors declare no competing interests.
References
MeSH terms
Substances
Grants and funding
- R01 DK119117/DK/NIDDK NIH HHS/United States
- K08 HL177169/HL/NHLBI NIH HHS/United States
- R01HL171201/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- R21AG077040/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- 1T32GM145407/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- K08HL140200/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- R01 HL163172/HL/NHLBI NIH HHS/United States
- HL145019/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- DK125722/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- K76AG064328/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- R01HL170058/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- R01 AG061034/AG/NIA NIH HHS/United States
- R35 HL155318/HL/NHLBI NIH HHS/United States
- 20CDA35310184/American Heart Association (American Heart Association, Inc.)
- 24SCEFIA1253853/American Heart Association (American Heart Association, Inc.)
- 461079553/Deutsche Forschungsgemeinschaft (German Research Foundation)
- DRG 120-17/Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation)
- R01 DK119117/DK/NIDDK NIH HHS/United States
- K08 HL177169/HL/NHLBI NIH HHS/United States
- R01 HL163172/HL/NHLBI NIH HHS/United States
- R01 AG061034/AG/NIA NIH HHS/United States
- R35 HL155318/HL/NHLBI NIH HHS/United States
LinkOut - more resources
- Full Text Sources
- Medical
- Molecular Biology Databases
